60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment
July 09, 2024 06:31 ET | Sixty Degrees Pharmaceuticals
60 Degrees Pharma wins IRB approval for tafenoquine study for treating persistent babesiosis in immunocompromised patients despite prior treatment.
Tevogen Logo Notified.png
Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social Responsibility
July 08, 2024 16:07 ET | Tevogen Bio Inc
WARREN, N.J., July 08, 2024 (GLOBE NEWSWIRE) -- Ryan Saadi, MD, MPH, founding CEO of Tevogen Bio (“Tevogen”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing...
Tevogen Logo Notified.png
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments
April 26, 2024 09:23 ET | Tevogen Bio Inc
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments
IncludeHealth, a digital musculoskeletal (MSK) health company, today announced a partnership with Yale New Haven Health System (YNHHS) to transform care for patients with musculoskeletal health conditions.
IncludeHealth to Provide Musculoskeletal Care in Patients’ Homes in Partnership with Yale New Haven Health
December 13, 2022 04:00 ET | IncludeHealth
CINCINNATI, OHIO, Dec. 13, 2022 (GLOBE NEWSWIRE) -- IncludeHealth, a digital musculoskeletal (MSK) health company, today announced a partnership with Yale New Haven Health System (YNHHS) to...
Algernon Logo 1.png
Algernon Pharmaceuticals Enters into a Clinical Trial Agreement with Yale University for a DMT Phase 2 Depression Study
October 24, 2022 07:00 ET | Algernon Pharmaceuticals
VANCOUVER, British Columbia, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical...
Researchers Investig
Researchers Investigate Nature’s Smallest “Social Cheaters”
September 14, 2022 12:30 ET | Burroughs Wellcome Fund
Research Triangle Park, N.C., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Being a member of a community often requires sacrifice. Species from across the animal kingdom have been shown to cooperate with...
Picture3.jpg
Yale’s Department of Psychiatry Chair to Join Clearmind Medicine
June 21, 2022 09:00 ET | Clearmind Medicine Inc.
Dr. John H. Krystal, world-leading expert in alcoholism and depression, will serve on scientific advisory board VANCOUVER, June 21, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND,...
Denver Grand Re-Opening
Blue Federal Credit Union Announces Grand Re-Opening of Denver Location
February 21, 2022 08:30 ET | Blue Federal Credit Union
Denver, Colorado, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Blue Federal Credit Union is excited to announce the grand re-opening of its south Denver branch located at 6460 East Yale Avenue. The opening...
Xanadu Logo.jpg
Xanadu Bio Obtains Licenses and Options to Novel Platform Technologies from Yale University to Develop an Intranasal SARS CoV-2 mRNA Vaccine Booster Aimed at Inducing Local Mucosal Immunity to Prevent SARS CoV-2 Infection and Virus Transmission
February 08, 2022 07:30 ET | Xanadu Bio
~ Company licenses PACE, a next generation polymeric nanoparticle delivery platform, and options intranasal PACE/Spike mRNA and Spike recombinant protein vaccine boosters for the treatment of...
logo-brainhq-hi-res-hori.png
Study: New Intervention Helps with Alcohol-related Cognitive Impairment
December 14, 2020 08:00 ET | Posit Science
SAN FRANCISCO, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Researchers at Yale published positive results from a pilot study of a novel combination therapy in patients with Mild Cognitive Impairment related...